PAPER Putcha D, Katsumi Y, Touroutoglou A, Eloyan A, Taurone A, Thangarajah M, Aisen P, Dage JL, Foroud T, Jack CR Jr, Kramer JH, Nudelman KN, Raman R, Vemuri P, Atri A, Day GS, Duara R, Graff-Radford NR, Grant IM, Honig LS, Johnson EC, Jones DT, Masdeu JC, Mendez MF, Musiek E, Onyike CU, Riddle M, Rogalski E, Salloway S, Sha S, Turner RS, Wingo TS, Wolk DA, Womack K, Carrillo MC, Rabinovici GD, Dickerson BC, Apostolova LG, Hammers DB, LEADS Consortium

Heterogeneous clinical phenotypes of sporadic early-onset Alzheimer's disease: a neuropsychological data-driven approach.

Alzheimers Res Ther. 2025 Feb 6;17(1):38. PubMed.

Paul Coleman

Arizona State University
United States

Julio Rojas

Memory and Aging Center, Weill Insititute for Neurosciences, University of California, San Francisco
United States

PAPER Koutsodendris N, Blumenfeld J, Agrawal A, Traglia M, Grone B, Zilberter M, Yip O, Rao A, Nelson MR, Hao Y, Thomas R, Yoon SY, Arriola P, Huang Y

Neuronal APOE4 removal protects against tau-mediated gliosis, neurodegeneration and myelin deficits.

Nat Aging. 2023 Mar;3(3):275-296. Epub 2023 Feb 20 PubMed.

PAPER Babu AT, Abdul Vahid A, Reselammal DS, Kizhakkeduth ST, Pinhero F, Vijayan V

Exploring the Potential Interaction between the Functional Prion Protein CPEB3 and the Amyloidogenic Pathogenic Protein Tau.

J Phys Chem B. 2025 Feb 5; Epub 2025 Feb 5 PubMed.

PAPER Lee BH, Cevizci M, Lieblich SE, Galea LA

Sex-specific influences of APOEε4 genotype on hippocampal neurogenesis and progenitor cells in middle-aged rats.

Biol Sex Differ. 2025 Feb 5;16(1):10. PubMed.

PAPER Hey JA, Yu JY, Abushakra S, Schaefer JF, Power A, Kesslak P, Paul J, Tolar M

Clinical Pharmacokinetics of Oral ALZ-801/Valiltramiprosate in a 2-Year Phase 2 Trial of APOE4 Carriers with Early Alzheimer's Disease.

Clin Pharmacokinet. 2025 Feb 5; Epub 2025 Feb 5 PubMed.

PAPER Zhu H, Huang C, Luo Z, Wu L, Cheng X, Wu H

Porphyromonas gingivalis Induces Disturbance of Kynurenine Metabolism Through the Gut-Brain Axis: Implications for Alzheimer's Disease.

J Dent Res. 2025 Feb 4;:220345241303141. Epub 2025 Feb 4 PubMed.

PAPER Han G, Xuewu G, Meng Z, Yuejing W, Yuchun W, Keshuang Z, Hongbo Y

Therapeutic effect of dihydroartemisinin on Alzheimer's disease model mice with senile macular degeneration.

Eur J Med Res. 2025 Feb 5;30(1):81. PubMed.

PAPER Gao W, Yang G, Liu X, Hu K, Pan J, Wang X, Zhao Y, Xu Y

Network pharmacology and experimental verification to investigate the mechanism of isoliquiritigenin for the treatment of Alzheimer's disease.

Sci Rep. 2025 Feb 5;15(1):4379. PubMed.

PAPER Zhang J, Yang Y, Zhang C, Wang Y, Su R, Qi W

Revealing the mechanism of two rimantadine derivatives inhibiting Aβ aggregation and destabilizing Aβ protofibrils by molecular dynamics simulation.

Colloids Surf B Biointerfaces. 2025 Jan 26;250:114538. Epub 2025 Jan 26 PubMed.

PAPER Li SH, Huang QH, Yang QQ, Huang Q, Wang DX, Yang J, Huang SH, Zhang SY, Wang JM, Xie LS, Yu SG, Wu QF

The shared mechanism of barrier dysfunction in ulcerative colitis and Alzheimer's disease: DDIT4/IL1β neutrophil extracellular traps drive macrophages-mediated phagocytosis.

Int Immunopharmacol. 2025 Feb 4;149:114188. Epub 2025 Feb 4 PubMed.

PAPER Mano T

RETRACTED: Mano, T. Application of Repetitive Transcranial Magnetic Stimulation over the Dorsolateral Prefrontal Cortex in Alzheimer's Disease: A Pilot Study. J. Clin. Med. 2022, 11, 798.

J Clin Med. 2025 Feb 5;14(3) PubMed. Retracted Paper.

PAPER He J, Sun S, Wang H, Ying Z, Tam KY

Triple-Target Inhibition of Cholinesterase, Amyloid Aggregation, and GSK3β to Ameliorate Cognitive Deficits and Neuropathology in the Triple-Transgenic Mouse Model of Alzheimer's Disease.

Neurosci Bull. 2025 Feb 5; Epub 2025 Feb 5 PubMed.

PAPER Darabi S, Gorgich EA, Moradi F, Rustamzadeh A

Lipidopathy disrupts peripheral and central amyloid clearance in Alzheimer's disease: Where are our knowledge.

IBRO Neurosci Rep. 2025 Jun;18:191-199. Epub 2025 Jan 9 PubMed.